Pharmaceutical composition for treatment of osteoporosis

Details Pharmaceutical composition for treatment of osteoporosis Pharmaceutical composition for treatment of osteoporosis

1990-10-25

1992-05-26

Rose, Shep K.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

A61K 31565, A61K 3724

Patent

active

051168286

ABSTRACT:
A pharmaceutical composition for the treatment of osteoporosis comprises an estrogen and a thyroid hormone as effective ingredients. By using the estrogen in combination with the thyroid hormone, a more excellent activity of increasing bone amount can be obtained than in the case of administering the estrogen alone.

REFERENCES:
patent: 4041022 (1977-08-01), Neher et al.
patent: 4590184 (1986-05-01), Maeda et al.
patent: 4692433 (1987-09-01), Hostetler et al.
patent: 4812304 (1989-03-01), Anderson et al.
patent: 4812311 (1989-03-01), Vchtman
patent: 4822609 (1989-04-01), Flora
patent: 4945103 (1990-07-01), Cohen
patent: 4946679 (1990-08-01), Thys-Jacobs
patent: 5001118 (1991-03-01), Maeda et al.
Glass Derwent Abstract 66-36744f/00 of FR.6435m, Bel 6.877713-A "Topical Compn of Sodium L-Thyroxine and an Estrogen: Synthetic or Natural eg. Stilbesterol, Diethylstilbestorol, Mestranol, Estrone, B-Estradiol, Ethinyl Estradoil, and Vitamin A".
Woodard Chem. Abstr. 74:50183k (1971).
Maeda Chem. Abstr. 77:56947w (1972).

Affiliated with

Also associated with

Rating

Pharmaceutical composition for treatment of osteoporosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical composition for treatment of osteoporosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for treatment of osteoporosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-419818